Introduction
The 2024–2025 influenza season in mainland China deviated significantly from historical norms, characterized by a delayed onset and the overwhelming dominance of the A(H1N1)pdm09 strain. This shift presents new challenges for public health surveillance and intervention strategies. The interplay between "immune debt" accrued during the COVID-19 pandemic and specific climatic conditions has altered the traditional "flu script," necessitating a re-evaluation of current predictive models and vaccination policies.
Methodology and Surveillance
Researchers utilized a multi-faceted approach to analyze the season's dynamics. Data from the National Sentinel Surveillance of Acute Respiratory Infectious Diseases (China CDC) provided insights into pathogen prevalence. This was complemented by epidemiological modeling using a "multidimensional influenza epidemic index" that integrates positivity rates and influenza-like illness (ILI) proportions. Furthermore, meteorological correlation studies examined variables such as temperature, humidity, and UV radiation across key regions, including Northeast China, Beijing, and the Northwest.
Environmental Drivers and the "Aridity Synergy"
Climate played a pivotal role in the 2024–2025 season. In Northwest China (specifically Xi’an and Lanzhou), a "low humidity + weak radiation" niche was identified as a significant driver. Reduced precipitation and sunlight were directly associated with a 4.5%–5.9% increase in influenza incidence, as viral aerosols tend to survive longer in dry, stagnant air. In Northeast China, a 5°C temperature drop correlated with a 25.04% rise in cases after a one-month lag, while extreme lows in Beijing saw the cumulative relative risk of infection skyrocket to 25.42.
The "Immune Debt" and Viral Dominance
The prolonged use of non-pharmaceutical interventions (NPIs) between 2020 and 2023 disrupted natural viral circulation, leading to a "lack of immune imprinting," particularly in children. This "immune debt" resulted in a 2.3-fold increase in susceptibility to emerging strains in 2025 models. The disruption was so profound that lineages like H3N2 and B/Yamagata faced regional extinctions, allowing A(H1N1)pdm09 to dominate, accounting for 97.4% of cases in specific clusters.
The Vaccination Challenge
A critical hurdle remains the "vaccination deficit." While the government has set a 90% coverage target for priority groups, actual rates for high-risk populations—including the elderly and those with chronic illnesses—remain below 15%. Nationally, China’s vaccination coverage stands at approximately 2.46%, significantly lower than international benchmarks like the United States (48.4%).
Conclusion and Future Directions
Addressing the evolving landscape of influenza in China requires a transition from reactive to proactive public health strategies. Key recommendations include:
- Vaccine Innovation: Accelerating the development of "influenza-COVID-19" combination vaccines to improve uptake.
- Enhanced Surveillance: Strengthening international genomic sequencing networks to better track antigenic drift.
- Community Outreach: Implementing mobile vaccination units to bridge the gap between current coverage and public health goals.
Despite these challenges, the continued use of effective NPIs, such as mask-wearing in crowded settings, remains essential, with the potential to reduce aerosol transmission by 40%–60%.
Summary updated